Biopharma Business

Tag "Dilaforette"

Swedish Fundraising brings Sickle Cell Disease Drug Closer to the Market

Modus Therapeutics has raised €3.4M to support the completion of a Phase II trial for sickle cell disease, a painful condition with no cure. Modus Therapeutics, previously Dilaforette, is developing sevuparin,

Read Full Article

Upcoming Events


The Magazine

New Subscriber

Subscribe Here